Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Disaggregation of Revenue [Line Items]
Net Revenue	$ 18,914	$ 22,676
Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	325	11
Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	18,589	22,665
U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	16,436	20,934
U.S. | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	0	0
U.S. | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	16,436	20,934
Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	2,478	1,742
Rest of World | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	325	11
Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	2,153	1,731
Product Sales – Point-in-time | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	18,589	22,665
Product Sales – Point-in-time | U.S. | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	16,436	20,934
Product Sales – Point-in-time | Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	2,153	1,731
License Fee – Over time | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	325	11
License Fee – Over time | U.S. | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	0	0
License Fee – Over time | Rest of World | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	$ 325	$ 11